**Supplementary Figure 1.** Receiver operator characteristic (ROC) curve analyses for weeks 6 and 14 infliximab concentrations stratifying patients with or without week 14 complete fistula response.



AUC: area under ROC curve

**Supplementary Figure 2.** Receiver operator characteristic (ROC) curve analyses for week 14 infliximab concentrations stratifying patients with or without week 14 CRP normalization.



CRP: C-reactive protein; AUC: area under ROC curve

**Supplementary Figure 3.** Receiver operator characteristic (ROC) curve analyses for weeks 2, 6 and 14 infliximab concentrations stratifying patients with or without week 14 composite remission.



AUC: area under ROC curve

**Supplementary Figure 4.** Rates of week 54 composite remission by week 14 infliximab concentration quartiles.



**Supplementary Figure 5.** Receiver operator characteristic (ROC) curve analyses for weeks 14 and 54 infliximab concentrations stratifying patients with or without week 54 composite remission.



AUC: area under ROC curve.

**Supplementary Table 1.** Infliximab concentrations by week 54 therapeutic outcomes status.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Infliximab concentration time point** | **Median (IQR) infliximab concentration per week 54 therapeutic outcomes** | | | |
|  |  | **Achieved** | **Not achieved** | **P-value** |
| **Week 2** | Fistula response | 26.1 (19.4-33.2) | 24.3 (19.5-31.7) | 0.393 |
| Complete fistula response | 24.5 (19.4-32.9) | 24.6 (19.5-33.1) | 0.970 |
| CRP normalization | 24.3 (17.1-33.1) | 23.9 (19.4-26.5) | 0.749 |
| Composite remission | 24.6 (18.4-33.1) | 23.6 (18.8-32.5) | 0.787 |
| **Week 6** | Fistula response | 18.7 (12.6-31.8) | 15.8 (9.2-22.3) | 0.021 |
| Complete fistula response | 18.2 (12.6-33.8) | 16.2 (9.2-23.2) | 0.048 |
| CRP normalization | 15.6 (10.4-33.5) | 14.5 (9.1-22.8) | 0.608 |
| Composite remission | 16.9 (13.9-36.4) | 13.7 (8.2-23.5) | 0.124 |
| **Week 14** | Fistula response | 6.4 (2.4-9.6) | 5.0 (1.9-8.9) | 0.009 |
| Complete fistula response | 6.2 (2.4-9.6) | 5.2 (2.0-8.7) | 0.179 |
| CRP normalization | 5.9 (2.4-15.2) | 3.4 (2.9-7.1) | 0.143 |
| Composite remission | 6.1 (4.4-27.3) | 4.5 (1.8-8.0) | 0.049 |
| **Week 30** | Fistula response | 2.8 (0.9-9.7) | 2.3 (0.4-6.6) | 0.257 |
| Complete fistula response | 2.3 (0.8-7.2) | 2.4 (0.6-8.7) | 0.962 |
| CRP normalization | 4.7 (1.3-11.9) | 1.1 (0.4-5.7) | 0.030 |
| Composite remission | 2.2 (0.9-8.9) | 2.4 (0.6-7.7) | 0.736 |
| **Week 46** | Fistula response | 1.8 (0.2-8.2) | 2.1 (0.2-6.9) | 0.670 |
| Complete fistula response | 2.0 (0.4-9.2) | 1.9 (0.2-6.8) | 0.472 |
| CRP normalization | 3.3 (0.8-13.5) | 0.9 (0.0-2.9) | 0.033 |
| Composite remission | 3.1 (1.5-16.4) | 1.1 (0.0-5.7) | 0.092 |
| **Week 54** | Fistula response | 1.9 (0.2-7.0) | 4.2 (0.3-8.5) | 0.687 |
| Complete fistula response | 3.2 (0.4-7.2) | 3.8 (0.2-6.8) | 0.773 |
| CRP normalization | 4.9 (1.6-9.2) | 1.0 (0.0-2.7) | 0.006 |
| Composite remission | 4.9 (1.9-10.6) | 1.6 (0.0-5.9) | 0.038 |

IQR: interquartile range, CRP: C-reactive protein.

**Supplementary Table 2.** Receiver operating characteristic (ROC) curve analyses of infliximab concentrations by week 54 therapeutic outcomes.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Week 54 therapeutic outcome** | **Infliximab concentration time point (week)** | **Threshold (µg/mL)** | **SN**  **(%)** | **SP**  **(%)** | **PPV**  **(%)** | **NPV**  **(%)** | **AUROC**  **(95% CI)** | **P-value** |
| **Fistula response** | 2 | 28.3 | 49 | 67 | 49 | 67 | 0.55 (0.44-0.65) | 0.397 |
| 6 | 9.6 | 90 | 31 | 45 | 83 | 0.62 (0.52-0.72) | 0.015 |
| 14 | 3.5 | 73 | 44 | 45 | 71 | 0.59 (0.49-0.69) | 0.085 |
| 30 | 0.5 | 86 | 26 | 44 | 73 | 0.56 (0.46-0.67) | 0.250 |
| 46 | 15.3 | 20 | 95 | 75 | 61 | 0.52 (0.41-0.64) | 0.673 |
| 54 | 6.6 | 30 | 73 | 44 | 59 | 0.52 (0.41-0.63) | 0.684 |
| **Complete fistula response** | 2 | 14.2 | 100 | 6 | 34 | 100 | 0.50 (0.40-0.60) | 0.970 |
| 6 | 9.6 | 90 | 29 | 39 | 86 | 0.61 (0.51-0.71) | 0.039 |
| 14 | 8.8 | 40 | 75 | 44 | 73 | 0.57 (0.47-0.68) | 0.181 |
| 30 | 0.1 | 93 | 16 | 35 | 81 | 0.50 (0.40-0.61) | 0.959 |
| 46 | 15.3 | 22 | 94 | 67 | 70 | 0.54 (0.42-0.66) | 0.478 |
| 54 | 1 | 72 | 38 | 38 | 72 | 0.52 (0.41-0.63) | 0.771 |
| **CRP normalization** | 2 | 31.5 | 44 | 76 | 61 | 59 | 0.47 (0.31-0.64) | 0.757 |
| 6 | 12.1 | 74 | 46 | 57 | 65 | 0.54 (0.39-0.70) | 0.607 |
| 14 | 4.3 | 71 | 53 | 59 | 67 | 0.61 (0.46-0.76) | 0.137 |
| 30 | 2.9 | 63 | 71 | 68 | 67 | 0.67 (0.53-0.82) | 0.021 |
| 46 | 1.7 | 68 | 67 | 70 | 64 | 0.67 (0.53-0.82) | 0.024 |
| 54 | 4.4 | 64 | 80 | 75 | 71 | 0.71 (0.57-0.85) | 0.003 |
| **Composite remission** | 2 | 32.7 | 42 | 75 | 31 | 82 | 0.53 (0.34-0.72) | 0.783 |
| 6 | 12.1 | 92 | 44 | 31 | 95 | 0.65 (0.48-0.82) | 0.090 |
| 14 | 2.4 | 100 | 35 | 29 | 100 | 0.69 (0.52-0.86) | 0.030 |
| 30 | 1.3 | 73 | 41 | 24 | 86 | 0.53 (0.34-0.73) | 0.720 |
| 46 | 1.7 | 75 | 58 | 35 | 88 | 0.66 (0.49-0.84) | 0.070 |
| 54 | 1.8 | 83 | 52 | 31 | 92 | 0.70 (0.54-0.85) | 0.013 |

SN: sensitivity, SP: specificity, PPV: positive predictive value, NPV: negative predictive value, AUROC: area under ROC curve, CI: confidence interval, CRP: C-reactive protein.

**Supplementary Table 3**. Variables associated with week 14 fistula response.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Univariate analysis** | | | **Multivariate analysis** | | |
| **Variables** | **p-value** | **OR** | **95%CI** | **p-value** | **OR** | **95%CI** |
| Gender: Male | 0.710 | 1.10 | 0.66-1.82 |  |  |  |
| Age | 0.815 | 1.00 | 0.98-1.03 |  |  |  |
| Albumin | 0.054 | 1.91 | 0.99-3.68 |  |  |  |
| CRP | 0.957 | 0.99 | 0.89-1.14 |  |  |  |
| Smoking history:  Nonsmoker  Current smoker  Former smoker | 0.298  0.067 | 1  1.38 0.55 | 0.75-2.54 0.3-1.04 |  |  |  |
| Concomitant IMMa | 0.488 | 0.81 | 0.45-1.47 |  |  |  |
| Concomitant corticosteroids | 0.998 | 1 | 0.57-1.75 |  |  |  |
| Prior segmental resection | 0.770 | 1.08 | 0.65-1.79 |  |  |  |
| Involved intestinal area:  Ileum and colon  Ileum  Colon | 0.744  0.839 | 1  1.13  1.06 | 0.55-2.30  0.60-1.87 |  |  |  |
| Draining fistulas > 1 | 0.163 | 1.43 | 0.86-2.39 |  |  |  |
| Perianal fistula location | 0.061 | 1.97 | 0.97-4.02 |  |  |  |
| Infliximab concentration at week 2 | 0.370 | 1.23 | 0.78-1.96 |  |  |  |
| Infliximab concentration at week 6 | 0.529 | 1.06 | 0.89-1.26 |  |  |  |
| Infliximab concentration at week 14 | 0.019 | 1.16 | 1.02-1.32 | 0.017 | 1.17 | 1.03-1.33 |

aThiopurines or methotrexate.

OR: odds ratio; CI: confidence interval; ATI: antibodies to infliximab; IMM: immunomodulators; CDAI: Crohn’s disease activity index; CRP: C-reactive protein.

**Supplementary Table 4**. Variables associated with week 54 fistula response.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Univariate analysis** | | | **Multivariate analysis** | | | |
| **Variables** | **p-value** | **OR** | **95%CI** | **p-value** | **OR** | **95%CI** |
| Gender: Male | 0.591 | 0.83 | 0.41-1.66 |  |  |  |
| Age | 0.291 | 1.02 | 0.98-1.05 |  |  |  |
| Albumin | 0.660 | 1.22 | 0.50-3.01 |  |  |  |
| CRP | 0.706 | 0.96 | 0.79-1.18 |  |  |  |
| Smoking history:  Nonsmoker  Current smoker  Former smoker | 0.626  0.684 | 1  1.23  1.21 | 0.54-2.80  0.49-3.00 |  |  |  |
| Concomitant IMMa | 0.020 | 0.26 | 0.08-0.81 | 0.020 | 0.26 | 0.08-0.81 |
| Concomitant corticosteroids | 0.038 | 0.41 | 0.17-0.95 |  |  |  |
| Prior segmental resection | 0.197 | 0.63 | 0.31-1.27 |  |  |  |
| Involved intestinal area:  Ileum and colon  Ileum  Colon | 0.794  0.045 | 1  1.14  2.24 | 0.42-3.11  1.02-4.95 |  |  |  |
| Draining fistulas > 1 | 0.475 | 0.77 | 0.38-1.57 |  |  |  |
| Perianal fistula location | 0.417 | 1.65 | 0.49-5.59 |  |  |  |
| Infliximab concentration at week 2 | 0.380 | 1.44 | 0.63-3.31 |  |  |  |
| Infliximab concentration at week 6 | 0.128 | 1.38 | 0.91-2.10 |  |  |  |
| Infliximab concentration at week 14 | 0.058 | 1.29 | 0.99-1.69 |  |  |  |
| Infliximab concentration at week 30 | 0.151 | 1.13 | 0.96-1.33 |  |  |  |
| Infliximab concentration at week 46 | 0.691 | 1.03 | 0.89-1.19 |  |  |  |
| Infliximab concentration at week 54 | 0.730 | 0.98 | 0.85-1.12 |  |  |  |

aThiopurines or methotrexate.

OR: odds ratio; CI: confidence interval; ATI: antibodies to infliximab; IMM: immunomodulators; CDAI: Crohn’s disease activity index; CRP: C-reactive protein.

**Supplementary Table 5**. Variables associated with week 14 complete fistula response.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Univariate analysis** | | | **Multivariate analysis** | | |
| **Variables** | **p-value** | **OR** | **95%CI** | **p-value** | **OR** | **95%CI** |
| Gender: Male | 0.546 | 0.87 | 0.54-1.38 |  |  |  |
| Age | 0.935 | 1.00 | 0.98-1.02 |  |  |  |
| Albumin | 0.015 | 2.19 | 1.16-4.14 |  |  |  |
| CRP | 0.937 | 1.00 | 0.90-1.10 |  |  |  |
| Smoking history:  Nonsmoker  Current smoker  Former smoker | 0.539  0.741 | 1  0.84  0.90 | 0.49-1.45  0.49-1.65 |  |  |  |
| Concomitant IMMa | 0.184 | 0.68 | 0.39-1.20 |  |  |  |
| Concomitant corticosteroids | 0.534 | 0.85 | 0.51-1.42 |  |  |  |
| Prior segmental resection | 0.423 | 1.21 | 0.76-1.94 |  |  |  |
| Involved intestinal area:  Ileum and colon  Ileum  Colon | 0.223  0.296 | 1  0.58  0.69 | 0.22-1.43  0.35-1.38 |  |  |  |
| Draining fistulas > 1 | <0.001 | 0.33 | 0.20-0.54 | <0.001 | 0.30 | 0.18-0.50 |
| Perianal fistula location | 0.025 | 2.31 | 1.11-4.84 | 0.016 | 2.60 | 1.19-5.68 |
| Infliximab concentration at week 2 | 0.335 | 1.25 | 0.8-1.95 |  |  |  |
| Infliximab concentration at week 6 | 0.396 | 1.08 | 0.91-1.28 |  |  |  |
| Infliximab concentration at week 14 | 0.013 | 1.18 | 1.03-1.34 | 0.019 | 1.18 | 1.03-1.35 |

aThiopurines or methotrexate.

OR: odds ratio; CI: confidence interval; ATI: antibodies to infliximab; IMM: immunomodulators; CDAI: Crohn’s disease activity index; CRP: C-reactive protein.

**Supplementary Table 6**. Variables associated with week 54 complete fistula response.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Univariate analysis** | | | **Multivariate analysis** | | | |
| **Variables** | **p-value** | **OR** | **95%CI** | **p-value** | **OR** | **95%CI** |
| Gender: Male | 0.455 | 0.76 | 0.36-1.58 |  |  |  |
| Age | 0.253 | 1.02 | 0.99-1.06 |  |  |  |
| Albumin | 0.598 | 1.29 | 0.50-3.34 |  |  |  |
| CRP | 0.739 | 0.96 | 0.77-1.20 |  |  |  |
| Smoking history:  Nonsmoker  Current smoker  Former smoker | 0.787  0.857 | 1  0.89  0.92 | 0.38-2.09  0.36-2.36 |  |  |  |
| Concomitant IMMa | 0.087 | 0.37 | 0.12-1.16 |  |  |  |
| Concomitant corticosteroids | 0.121 | 0.49 | 0.20-1.20 |  |  |  |
| Prior segmental resection | 0.183 | 0.61 | 0.29-1.27 |  |  |  |
| Involved intestinal area:  Ileum and colon  Ileum  Colon | 0.881  0.358 | 1  1.08  1.47 | 0.38-3.05  0.65-3.32 |  |  |  |
| Draining fistulas > 1 | 0.028 | 0.43 | 0.21-0.92 | 0.028 | 0.43 | 0.21-0.92 |
| Perianal fistula location | 0.382 | 1.81 | 0.48-6.86 |  |  |  |
| Infliximab concentration at week 2 | 0.904 | 0.95 | 0.4-2.26 |  |  |  |
| Infliximab concentration at week 6 | 0.212 | 1.30 | 0.86-1.97 |  |  |  |
| Infliximab concentration at week 14 | 0.116 | 1.25 | 0.95-1.65 |  |  |  |
| Infliximab concentration at week 30 | 0.631 | 1.04 | 0.88-1.23 |  |  |  |
| Infliximab concentration at week 46 | 0.525 | 1.05 | 0.90-1.22 |  |  |  |
| Infliximab concentration at week 54 | 0.675 | 1.03 | 0.89-1.19 |  |  |  |

aThiopurines or methotrexate

OR: odds ratio; CI: confidence interval; ATI: antibodies to infliximab; IMM: immunomodulators; CDAI: Crohn’s disease activity index; CRP: C-reactive protein.

**Supplementary Table 7**. Variables associated with week 14 CRP normalization.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Univariate analysis** | | | | **Multivariate analysis** | | |
| **Variables** | **p-value** | **OR** | **95%CI** | **p-value** | | **OR** | **95%CI** |
| Gender: Male | 0.413 | 1.3 | 0.70-2.43 |  | |  |  |
| Age | 0.750 | 1.00 | 0.98-1.03 |  | |  |  |
| Albumin | 0.536 | 1.31 | 0.56-3.04 |  | |  |  |
| CRP | 0.090 | 0.88 | 0.76-1.02 |  | |  |  |
| Smoking history:  Nonsmoker  Current smoker  Former smoker | 0.995  0.924 | 1  1.00  1.04 | 0.49-2.06  0.45-2.39 |  | |  |  |
| Concomitant IMM | 0.281 | 0.66 | 0.31-1.41 |  | |  |  |
| Concomitant corticosteroids | 0.809 | 1.09 | 0.54-2.18 |  | |  |  |
| Prior segmental resection | 0.648 | 0.86 | 0.46-1.62 |  | |  |  |
| Involved intestinal area:  Ileum and colon  Ileum  Colon | 0.206  0.927 | 1  0.53  0.97 | 0.20-1.42  0.49-1.93 |  | |  |  |
| Draining fistulas > 1 | 0.128 | 0.61 | 0.32-1.15 |  | |  |  |
| Perianal fistula location | 0.035 | 3.42 | 1.09-10.74 | 0.021 | | 3.95 | 1.22-12.78 |
| Infliximab concentration at week 2 | 0.683 | 1.15 | 0.59-2.23 |  | |  |  |
| Infliximab concentration at week 6 | 0.183 | 1.18 | 0.92-1.52 |  | |  |  |
| Infliximab concentration at week 14 | <0.001 | 1.43 | 1.16-1.76 | <0.001 | | 1.46 | 1.18-1.80 |

aThiopurines or methotrexate.

OR: odds ratio; CI: confidence interval; ATI: antibodies to infliximab; IMM: immunomodulators; CDAI: Crohn’s disease activity index; CRP: C-reactive protein.

**Supplementary Table 8**. Variables associated with week 54 CRP normalization.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Univariate analysis** | | | **Multivariate analysis** | | | |
| **Variables** | **p-value** | **OR** | **95%CI** | **p-value** | **OR** | **95%CI** |
| Gender: Male | 0.799 | 1.14 | 0.41-3.20 |  |  |  |
| Age | 0.334 | 1.02 | 0.98-1.08 |  |  |  |
| Albumin | 0.330 | 1.92 | 0.52-7.13 |  |  |  |
| CRP | 0.443 | 0.89 | 0.67-1.19 |  |  |  |
| Smoking history:  Nonsmoker  Current smoker  Former smoker | 0.790  0.598 | 1  1.19  1.45 | 0.34-4.19  0.37-5.07 |  |  |  |
| Concomitant IMMa | 0.080 | 3.60 | 0.85-15.31 |  |  |  |
| Concomitant corticosteroids | 0.649 | 1.31 | 0.40-4.27 |  |  |  |
| Prior segmental resection | 0.586 | 0.75 | 0.27-2.11 |  |  |  |
| Involved intestinal area:  Ileum and colon  Ileum  Colon | 0.341  0.611 | 1  0.42  1.36 | 0.07-2.42  0.41-4.47 |  |  |  |
| Draining fistulas > 1 | 0.260 | 1.85 | 0.63-5.38 |  |  |  |
| Perianal fistula location | 0.586 | 0.60 | 0.09-3.86 |  |  |  |
| Infliximab concentration at week 2 | 0.741 | 0.81 | 0.23-2.83 |  |  |  |
| Infliximab concentration at week 6 | 0.303 | 1.32 | 0.78-2.24 |  |  |  |
| Infliximab concentration at week 14 | 0.239 | 1.22 | 0.87-1.72 |  |  |  |
| Infliximab concentration at week 30 | 0.046 | 1.32 | 1.00-1.74 |  |  |  |
| Infliximab concentration at week 46 | 0.048 | 1.24 | 1.00-1.53 |  |  |  |
| Infliximab concentration at week 54 | 0.024 | 1.29 | 1.03-1.60 |  |  |  |

aThiopurines or methotrexate.

OR: odds ratio; CI: confidence interval; ATI: antibodies to infliximab; IMM: immunomodulators; CDAI: Crohn’s disease activity index; CRP: C-reactive protein.

**Supplementary Table 9**. Variables associated with week 14 composite remission.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Univariate analysis** | | | **Multivariate analysis** | | | |
| **Variables** | **p-value** | **OR** | **95%CI** | **p-value** | **OR** | **95%CI** |
| Gender: Male | 0.585 | 0.81 | 0.39-0.71 |  |  |  |
| Age | 0.479 | 0.99 | 0.95-1.02 |  |  |  |
| Albumin | 0.335 | 0.67 | 0.59-4.73 |  |  |  |
| CRP | 0.732 | 0.97 | 0.84-1.13 |  |  |  |
| Smoking history:  Nonsmoker  Current smoker  Former smoker | 0.645  0.911 | 1  0.82  0.95 | 0.35-1.93  0.36-2.50 |  |  |  |
| Concomitant IMM | 0.902 | 0.95 | 0.39-2.30 |  |  |  |
| Concomitant corticosteroids | 0.437 | 0.71 | 0.29-1.70 |  |  |  |
| Prior segmental resection | 0.450 | 1.33 | 0.63-2.82 |  |  |  |
| Involved intestinal area:  Ileum and colon  Ileum  Colon | 0.092  0.597 | 1  0.27  0.81 | 0.06-1.24  0.36-1.80 |  |  |  |
| Draining fistulas > 1 | 0.006 | 0.35 | 0.16-0.74 |  |  |  |
| Perianal fistula location | NAb | NAb | NAb |  |  |  |
| Infliximab concentration at week 2 | 0.177 | 1.73 | 0.78-3.81 |  |  |  |
| Infliximab concentration at week 6 | 0.060 | 1.46 | 0.98-2.19 |  |  |  |
| Infliximab concentration at week 14 | <0.001 | 2.32 | 1.55-3.49 | <0.001 | 2.32 | 1.55-3.49 |

aThiopurines or methotrexate; bThis was suppressed because of zero cell counts in one of the 2x2 tables.

OR: odds ratio; CI: confidence interval; ATI: antibodies to infliximab; IMM: immunomodulators; CDAI: Crohn’s disease activity index; CRP: C-reactive protein.

**Supplementary Table 10**. Variables associated with week 54 composite remission.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Univariate analysis** | | | **Multivariate analysis** | | | |
| **Variables** | **p-value** | **OR** | **95%CI** | **p-value** | **OR** | **95%CI** |
| Gender: Male | 0.251 | 0.46 | 0.12-1.74 |  |  |  |
| Age | 0.591 | 1.02 | 0.96-1.08 |  |  |  |
| Albumin | 0.831 | 0.85 | 0.18-3.98 |  |  |  |
| CRP | 0.815 | 1.04 | 0.74-1.45 |  |  |  |
| Smoking history:  Nonsmoker  Current smoker  Former smoker | 0.706  0.607 | 1  0.75  0.64 | 0.17-3.35  0.12-3.46 |  |  |  |
| Concomitant IMMa | 0.819 | 0.82 | 0.15-4.43 |  |  |  |
| Concomitant corticosteroids | 0.15 | 0.21 | 0.02-1.77 |  |  |  |
| Prior segmental resection | 0.307 | 0.50 | 0.13-1.89 |  |  |  |
| Involved intestinal area:  Ileum and colon  Ileum  Colon | NA  0.119 | 1  NA  2.90 | NA  0.76-11.08 |  |  |  |
| Draining fistulas > 1 | 0.873 | 0.90 | 0.25-3.27 |  |  |  |
| Perianal fistula location | 0.968 | 1.05 | 0.11-10.34 |  |  |  |
| Infliximab concentration at week 2 | 0.875 | 1.13 | 0.25-5.10 |  |  |  |
| Infliximab concentration at week 6 | 0.076 | 2.23 | 0.92-5.45 |  |  |  |
| Infliximab concentration at week 14 | 0.023 | 2.05 | 1.10-3.82 | 0.023 | 2.05 | 1.10-3.82 |
| Infliximab concentration at week 30 | 0.525 | 1.11 | 0.80-1.53 |  |  |  |
| Infliximab concentration at week 46 | 0.098 | 1.27 | 0.96-1.69 |  |  |  |
| Infliximab concentration at week 54 | 0.053 | 1.45 | 1.00-2.10 |  |  |  |

aThiopurines or methotrexate.

OR: odds ratio; CI: confidence interval; ATI: antibodies to infliximab; IMM: immunomodulators; CDAI: Crohn’s disease activity index; CRP: C-reactive protein; NA: not applicable.